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AT1 receptor blocker
inhibitors (ACE-Is) and ﬁrst generation ARBs. In the present study,
hence, we used olmesartan among RAS inhibitors to elucidate the pre-
cise role of AT1-receptor in HFpEF, and to examine the hypothesis that
strong AT1-receptor blockade can clinically improve HFpEF through
the inhibition of endothelial dysfunction. We deﬁned HFpEF clinically
according to the criteria of the European Working Group to HFpEF [5].
After the optimal therapy for HF, cardiac diastolic function estimated
by echocardiography, peripheral vascular endothelial function assessed
by ﬁngertip-digital-reactive hyperemia-peripheral arterial tonometry
(RH-PAT) using Endo-PAT2000, and blood various biomarkers at stableThe optimal treatment for heart failure (HF)with preserved left ven-
tricular ejection fraction (LVEF) (HFpEF) has not been established [1],
because the precise pathophysiological mechanism underlying HFpEF
still remains unclear. Using experimental models of HFpEF, we previ-
ously reported a novel mechanism underlying reversal of endothelial
dysfunction and HFpEF by antioxidant effects by AT1-receptor block-
ade [2]. Furthermore, we recently demonstrated the clinical signiﬁ-
cance of derivatives of reactive oxidative metabolites (DROM, Diacron
srl, Grosseto, Italy), a novel biomarker of reactive oxygen species
(ROS), in HFpEF patients [3]. Hence, by performing this study (ORION:
OlmesaRtan Improvement endothelial functiON with hypertension
study), we examined the clinical therapeutic effect of AT1-receptor
blocker (ARB) on HFpEF patients.
We examined prospectively 20 hypertensive HFpEF patients,
hospitalized in Kumamoto-University Hospital and taking any renin–
angiotensin system (RAS) inhibitor other than highly-selective ARB;
olmesartan for anti-hypertensive therapy, and switched to appreciable
amounts of olmesartan. Olmesartan, a second generation ARB, has im-
portant interactions to evoke inverse agonism, so called “double-chain
domain” [4], resulting in stronger angiotensin II blockade via highcular Medicine, Faculty of Life
University, 1-1-1 Honjo, Chuo-
amoto).
land Ltd. This is an open access articlcondition, and they were compared before (at the time of discharge)
and 3-months after (at the visit in outpatient clinic) treatments of
olmesartan. Non-invasive RH-PAT was performed with the patient in
the supine position and both hands on the same level in a comfortable,
thermoneutral environment.
11 of 20 HFpEF patients (55%) were taking ACEIs (enalapril 6,
imidapril 5) and other 9 patients (45%) had the ﬁrst generation ARBs
(losartan 1, valsartan 5, candesartan 3). Other baseline characteristics
of patients are shown in Table 1. Lipid proﬁles and renal functions in
HFpEF patients were not changed by olmesartan treatments. Further-
more, the switch of antihypertensive drugs to olmesartan (average dos-
age amounts: 22.9 mg/day) didn't signiﬁcantly affect systolic- and
diastolic-blood pressure, heart rate, body mass index and abdominal
circumference in HFpEF patients. Despite no additive hypotensive
effects of olmesartan, endothelial dysfunctionwas signiﬁcantly reversed
(RH-index [RHI]; 1.57 ± 0.34 to 1.87 ± 0.50, P = 0.034), accompanied
by signiﬁcant reduction of serumDROM levels (normal range; 250–300
unit called the Carratelli unit [U.CARR]; 362.8 ± 13.7 to 302.1 ±
9.4 U.CARR, P= 0.001) (Table 1). Furthermore, olmesartan signiﬁcantly
improved cardiac diastolic dysfunction evaluated by the ratio of early-
transmitral-ﬂow velocity to tissue Doppler early-diastolic-mitral annu-
lar velocity (E/e′) (15.4 [11.0–21.4] to 11.0 [6.4–18.0], P b 0.001), but not
LVEF and LV anteriorwall thickness in echocardiography, and decreased
plasmaBNP levels (60.2±75.1 to 22.7±20.4 pg/mL, P b 0.05) inHFpEF
patients (Table 1). Additionally, olmesartan signiﬁcantly increased
plasma superoxide dismutase (SOD) activity (2.39 ± 0.73 to 3.06 ±e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Changes inparameters of 20HFpEF patients before and after the treatments of olmesartan.
Before the
treatments
(n = 20)
After the
treatments
(n = 20)
P valuea
Dosages of olmesartan 22.9 (7.2) 22.1 (8.5) n.s.
Systolic blood pressure (mm Hg) 135.6 (17.7) 130.4 (20.7) n.s.
Diastolic blood pressure (mm Hg) 76.9 (11.2) 75.0 (11.6) n.s.
Heart rate (bpm) 70.3 (13.2) 66.1 (10.5) n.s.
Body mass index 25.7 (3.1) 25.8 (2.7) n.s.
abdominal circumference (cm) 91.1 (9.4) 91.4 (8.2) n.s.
Hypertension (yes, %) 89.1 89.6 n.s.
LDL-Cho (mg/dL) 103.6 (38.5) 87.2 (29.9) n.s.
HDL-Cho (mg/dL) 48.6 (8.6) 49.9 (11.2) n.s.
Triglycerides (mg/dL) 130.3 (69.6) 112.7 (59.7) n.s.
Glucose (mg/dl) 125.5 (51.3) 107.1 (20.4) n.s.
Hb A1c (%) 6.42 (1.79) 6.01 (0.82) n.s.
eGFR (mL/min/1.73 m2) 72.6 (20.9) 67.3 (17.8) n.s.
Creatinine (mg/dL) 0.80 (0.24) 0.76 (0.27) n.s.
BUN (mg/dL) 16.4 (4.0) 15.8 (4.9) n.s.
Na 140.2 (1.2) 140.2 (1.4) n.s.
K 4.3 (0.4) 4.6 (0.4) n.s.
RHI 1.57 (0.34) 1.87 (0.50) 0.034
LVEF (%) 63.5 (5.5) 63.3 (5.5) n.s.
E/e′ 15.4 (3.2) 11.0 (3.4) b0.001
LVAW thickness (mm) 11.8 (3.0) 11.2 (2.5) n.s.
Serum DROM levels (U.CARR) 362.8 (13.7) 302.1 (9.4) 0.001
Plasma BNP levels (pg/mL) 60.2 (75.1) 22.7 (20.4) b0.05
Plasma SOD activity (U/mL) 2.39 (0.73) 3.06 (0.78) 0.02
Plasma adiponectin levels (μg/mL) 2.66 (1.55) 4.12 (1.99) b0.05
Plasma NO3−/NO2− levels (μmol/L) 53.2 ± 28.1 62.9 ± 28.4 n.s.
Data are mean (standard deviation), median (25th to 75th percentile range), or number
(percentage).
HF: heart failure, HFpEF: heart failure with preserved left ventricular ejection fraction,
BMI: body mass index, CAD: coronary artery disease, DM: diabetes mellitus, Hb A1c:
hemoglobin A1c, LDL-Cho: low-density lipoprotein cholesterol, HDL-Cho: high-density
lipoprotein cholesterol, BNP: B-type natriuretic peptide, eGFR: estimated glomerular
ﬁltration rate, LVEF: left ventricular ejection fraction, E/e′: the ratio of early transmitral
ﬂow velocity to tissue Doppler early diastolic mitral annular velocity, LVAW: left ventric-
ular anterior wall, ACEIs: angiotensin-converting enzyme inhibitors, ARBs: angiotensin II
receptor blockers, CCB: calcium channel blockers, HMG-CoA RI: hydroxymethylglutaryl
coenzyme A reductase inhibitors, BUN: blood urea nitrogen, Na: sodium, K: potassium,
RHI: reactive hyperemia peripheral arterial tonometry index, DROM: derivatives of reac-
tive oxygen metabolites, U.CARR: unit called the Carratelli unit, BNP: B-type natriuretic
peptide, SOD: superoxide dismutase, NO3−/NO2−: nitrates-and-nitrite.
a Comparison between before and after the treatments of olmesartan for HFpEF
patients.
129E. Yamamoto et al. / IJC Heart & Vasculature 8 (2015) 128–1300.78 U/mL, P = 0.02) and adiponectin levels (2.66 ± 1.55 to 4.12 ±
1.99μg/mL,Pb0.05),butnotaffectplasmanitratesandnitrites(NO3−/
NO2−) levels (53.2 ± 28.1 to 62.9 ± 28.4 μmol/L) (Table 1). Thus, strong
AT1-receptor blockade by olmesartan restored not only endothelial
dysfunction but also cardiac diastolic dysfunction in HFpEF patients
beyond hypotensive effects.
Several studies reported that ROS were closely associated with the
pathophysiology of endothelial dysfunction in various cardiovascular
diseases [6], and we reported that peripheral vascular endothelial
function, assessed by RH-PAT, is signiﬁcantly impaired [7] and ROS, indi-
cated by increased serumDROMvalues,were signiﬁcantly overproduced
in HFpEF patients than in non-HF patients [3]. In this study, actually,
both peripheral endothelial dysfunction and ROS overproduction signif-
icantly occurred in HFpEF patients. Furthermore, strong AT1-receptor
blockade by olmesartan signiﬁcantly decreased ROS and improved en-
dothelial dysfunction in HFpEF, consistent with our basic research
usingHFpEFmodel rats [2]. Moreover, our previous basic research dem-
onstrated that AT1-receptor blockade also reversed cardiac diastolic
dysfunction and inhibited cardiac death of HFpEF rats [2]. Likewise,
the present clinical study showed that olmesartan signiﬁcantly im-
proved HF, indicating that AT1-receptor is deeply involved in the path-
ophysiology of HFpEF.
As described above, the precise pathophysiological mechanism
underlying HFpEF remains unknown. Although ROS might be one ofthe major risk factors for the development of HFpEF [8], the mecha-
nisms of ROS overproduction in HFpEF are not fully understood. In
this study, olmesartan signiﬁcantly increased SOD activities, but not
nitric oxide (NO) levels, indicating that angiotensin receptor-induced
SOD inactivationmight involve in ROS overproduction inHFpEF. Actually,
previous reports showed that angiotensin II-decreased SOD activation in
cardiovascular diseases [9]. Adiponectin, one of the anti-atherogenic
adipokines, was reported to be downregulated by angiotensin II-
induced ROS [10]. Therefore, some ARBs were reported to inhibit ROS
and upregulate adiponectin, leading to the improvement of endothelial
dysfunction as well as the beneﬁcial effects of olmesartan demonstrated
in this study. Thus, we conﬁrmed that increased SOD, but not NO activ-
ities, might contribute to beneﬁcial effects of ARB for endothelial func-
tion and cardiac diastolic function in HFpEF. However, further
investigations are needed to elucidate detailed mechanisms and in-
volvements of ROS in HFpEF.
HFpEF patients have a poor prognosis equivalent to that with HF
with reduced LVEF patients. Therefore, identiﬁcation of effective thera-
peutic strategy for HFpEF has great clinical importance. No clinical study
demonstrated the efﬁcacy of RAS inhibitors for the management of
HFpEF, however this study showed that olmesartan clinically improved
endothelial dysfunction and cardiac diastolic dysfunction, both ofwhich
are known to be associated with adverse clinical outcome of HFpEF.
These results indicate that olmesartan could contribute to the improve-
ment of prognosis in HFpEF.
Drug-induced changes in endothelial function should be performed
ideally in a cross-over matter, in particular with such small-sample-
sized study. Cross-over or further large studies are required to deter-
mine the exact signiﬁcance of olmesartan in HFpEF patients. Despite
the limitation, this study clearly showed the beneﬁcial effects of highly-
selective AT1-receptor blockade by olmesartan in HFpEF, indicating
the useful therapeutic strategy of strong AT1-receptor blockade for
HFpEF.
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